SkinBioTherapeutics PLC (SBTX)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

19.00p

Buy

20.00p

arrow-down-0.20p (-1.01%)

SkinBioTherapeutics PLC is a life science company. The company is engaged in the development of technology to protect, manage and restore skin utilising proteins found in human microbiota.
Prices updated at 15 May 2025, 09:21 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Martin Braddock Hunt
CEO
Mr. Stuart John Ashman
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
15
Head office
Bath Lane
Newcastle upon Tyne
United Kingdom
NE4 5TF
mobile
+44 1914957325
letter
Investorrelations@skinbiotherapeutics.com

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Martin Braddock Hunt
Non-Executive Director, Chairman
---0.07m-
Dr. Catherine Denise Prescott
Non-Executive Director
---0.04m-
Ms. Danielle Bekker
Non-Executive Director
-----
Mr. Stuart John Ashman
Executive Director, Chief Executive Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Unicorn Asset Management Ltd7,894,7360.89958--30 Apr 20253.40
Unicorn AIM VCT Series 3 ORD7,894,7360.89958--30 Apr 20253.40
Miton UK Microcap2,117,8700.86528--30 Apr 20250.91
Evelyn Partners Investment Management LLP---1262433-30 Apr 2025-
Miton Asset Management Limited---2682130-30 Apr 2025-

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.